Tiziana Life Sciences plc
TLSA
|
News
|
$0.6698
4.66%
4.45%
600K
|
Health Technology
(0.0% 1d) (44.4% 1m) (-35.6% 1y) (15.5% 2d) (21.4% 3d) (34.0% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 68,502,197
http://www.tizianalifesciences.com
Sec Filling | Patents | 10 employees
Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.
covid antibody monoclonal antibodies immunology cd73 anti-cd3
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10